Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up (scientific article published on 21 July 2005)

Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group

Q28372204

Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors

Q28372640

Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients

Q33173746

Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease

Q33613318

Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma

Q34150824

Recent advances in the prevention of anthracycline cardiotoxicity in childhood

Q34372974

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis

Q34659375

Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology

Q36817729

Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction

Q37429228

Strategies for prevention of anthracycline cardiotoxicity

Q40875208

Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring

Q40952341

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

Q41142694

Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.

Q41711347

Anthracycline-induced cardiotoxicity in children and young adults

Q41741113

Clinical spectrum of anthracycline antibiotic cardiotoxicity

Q41765974

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Q42279363

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

Q42537936

Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy

Q42538949

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

Q42556370

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

Q43918795

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

Q44028634

New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy

Q47897197

Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children.

Q52931320

Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group

Q68114949

Anthracycline-induced cardiotoxicity

Q71112913

Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results

Q73419790

Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood

Q74607086

Strategies for reduction of anthracycline cardiac toxicity

Q77448220

Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study

Q77880609

P433

issue

P921

main subject

echocardiography

Q216933

P304

page(s)

128-136

P577

publication date

2005-07-21

P1433

published in

Supportive Care in Cancer

Q15766919

P1476

title

Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up

P478

volume

Reverse relations

cites work (P2860)

Q36609442	Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
Q35849444	Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Q37057941	Detection and monitoring of cardiotoxicity-what does modern cardiology offer?
Q34073681	Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
Q38264693	Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines
Q57459923	Early and late complications following hematopoietic stem cell transplantation in pediatric patients - A retrospective analysis over 11 years
Q89735701	Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
Q93167028	Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity
Q36568915	Iron chelators with topoisomerase-inhibitory activity and their anticancer applications
Q36568908	Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Q34392758	Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitro
Q37338134	Recent advances in protection against doxorubicin-induced toxicity
Q28088408	Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer

P356	DOI	10.1007/S00520-005-0858-8
P698	PubMed publication ID	16034614